Evidence map›Paper›PMID 34452630›Full record

ReviewClinical epigenetics2021

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application.

Chunhong Hu, Xiaohan Liu, Yue Zeng, Junqi Liu, Fang Wu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chunhong Hu *Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Xiaohan Liu *Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Yue ZengDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Junqi LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Fang WuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. wufang4461@csu.edu.cn.ORCID 0000-0002-6627-3437
Central South University · CN

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-HS2017-043Central South University 201212200021Hunan Health Commission project B2017016National Natural Science Foundation of China 81902351Natural Science Foundation of Hunan Province 2018JJ2586
6 · The paper itself

Abstract

DNA methylation, an epigenetic modification, regulates gene transcription and maintains genome stability. DNA methyltransferase (DNMT) inhibitors can activate silenced genes at low doses and cause cytotoxicity at high doses. The ability of DNMT inhibitors to reverse epimutations is the basis of their use in novel strategies for cancer therapy. In this review, we examined the literature on DNA methyltransferase inhibitors. We summarized the mechanisms underlying combination therapy using DNMT inhibitors and clinical trials based on combining hypomethylation agents with other chemotherapeutic drugs. We also discussed the efficacy of such compounds as antitumor agents, the need to optimize treatment schedules and the regimens for maximal biologic effectiveness. Notably, the combination of DNMT inhibitors and chemotherapy and/or immune checkpoint inhibitors may provide helpful insights into the development of efficient therapeutic approaches.

Indexed as

Antineoplastic AgentsDNA MethylationDNA Modification MethylasesEnzyme InhibitorsEpigenesis, GeneticHumansNeoplasmsAntineoplastic AgentsDNA Modification MethylasesEnzyme Inhibitors

Identifiers

PMID34452630
PMCPMC8394595
OpenAlexW3195739405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.